193 related articles for article (PubMed ID: 19962921)
1. An adult Xp11.2 translocation renal carcinoma showing response to treatment with sunitinib.
Pwint TP; Macaulay V; Roberts IS; Sullivan M; Protheroe A
Urol Oncol; 2011; 29(6):821-4. PubMed ID: 19962921
[TBL] [Abstract][Full Text] [Related]
2. Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma.
Choueiri TK; Lim ZD; Hirsch MS; Tamboli P; Jonasch E; McDermott DF; Dal Cin P; Corn P; Vaishampayan U; Heng DY; Tannir NM
Cancer; 2010 Nov; 116(22):5219-25. PubMed ID: 20665500
[TBL] [Abstract][Full Text] [Related]
3. A case of adult metastatic Xp11 translocation renal cell carcinoma treated successfully with sunitinib.
Choueiri TK; Mosquera JM; Hirsch MS
Clin Genitourin Cancer; 2009 Oct; 7(3):E93-4. PubMed ID: 19815489
[TBL] [Abstract][Full Text] [Related]
4. Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network.
Malouf GG; Camparo P; Oudard S; Schleiermacher G; Theodore C; Rustine A; Dutcher J; Billemont B; Rixe O; Bompas E; Guillot A; Boccon-Gibod L; Couturier J; Molinié V; Escudier B
Ann Oncol; 2010 Sep; 21(9):1834-1838. PubMed ID: 20154303
[TBL] [Abstract][Full Text] [Related]
5. Sunitinib-induced nephrotic syndrome in association with drug response in a patient with Xp11.2 translocation renal cell carcinoma.
Liu YC; Chang PM; Liu CY; Yang CY; Chen MH; Pan CC; Chen MH
Jpn J Clin Oncol; 2011 Nov; 41(11):1277-81. PubMed ID: 21965162
[TBL] [Abstract][Full Text] [Related]
6. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib.
Zimmermann K; Schmittel A; Steiner U; Asemissen AM; Knoedler M; Thiel E; Miller K; Keilholz U
Oncology; 2009; 76(5):350-4. PubMed ID: 19321976
[TBL] [Abstract][Full Text] [Related]
7. Persistent complete response after single-agent sunitinib treatment in a case of TFE translocation positive relapsed metastatic pediatric renal cell carcinoma.
Chowdhury T; Prichard-Jones K; Sebire NJ; Bier N; Cherian A; Sullivan MO; O'Meara A; Anderson J
J Pediatr Hematol Oncol; 2013 Jan; 35(1):e1-3. PubMed ID: 22995920
[TBL] [Abstract][Full Text] [Related]
8. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
[TBL] [Abstract][Full Text] [Related]
9. Sunitinib in patients with metastatic renal cell carcinoma.
Motzer RJ; Rini BI; Bukowski RM; Curti BD; George DJ; Hudes GR; Redman BG; Margolin KA; Merchan JR; Wilding G; Ginsberg MS; Bacik J; Kim ST; Baum CM; Michaelson MD
JAMA; 2006 Jun; 295(21):2516-24. PubMed ID: 16757724
[TBL] [Abstract][Full Text] [Related]
10. Sunitinib in advanced metastatic non-clear cell renal cell carcinoma: a single institution retrospective study.
Paglino C; Imarisio I; Ganini C; Morbini P; Vercelli A; Bregant C; Porta C
Future Oncol; 2012 Dec; 8(12):1605-12. PubMed ID: 23231522
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
[TBL] [Abstract][Full Text] [Related]
12. Computed tomography characteristics of unresectable primary renal cell carcinoma treated with neoadjuvant sunitinib.
Salem ME; Shah SN; Elson P; Garcia JA; Wood LS; Medsinge A; Campbell S; Dreicer R; Rini BI
Clin Genitourin Cancer; 2014 Apr; 12(2):117-23. PubMed ID: 24126239
[TBL] [Abstract][Full Text] [Related]
13. Xp11 translocation renal cell carcinoma morphologically mimicking clear cell-papillary renal cell carcinoma in an adult patient: report of a case expanding the morphologic spectrum of Xp11 translocation renal cell carcinomas.
Parihar A; Tickoo SK; Kumar S; Arora VK
Int J Surg Pathol; 2015 May; 23(3):234-7. PubMed ID: 25519951
[TBL] [Abstract][Full Text] [Related]
14. A case study of metastatic Xp11.2 translocation renal cell carcinoma effectively treated with sunitinib.
Numakura K; Tsuchiya N; Yuasa T; Saito M; Obara T; Tsuruta H; Narita S; Horikawa Y; Satoh S; Habuchi T
Int J Clin Oncol; 2011 Oct; 16(5):577-80. PubMed ID: 21161315
[TBL] [Abstract][Full Text] [Related]
15. Prolonged complete responses and near-complete responses to sunitinib in metastatic renal cell carcinoma.
Heng DY; Rini BI; Garcia J; Wood L; Bukowski RM
Clin Genitourin Cancer; 2007 Dec; 5(7):446-51. PubMed ID: 18272027
[TBL] [Abstract][Full Text] [Related]
16. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy.
Tamaskar I; Garcia JA; Elson P; Wood L; Mekhail T; Dreicer R; Rini BI; Bukowski RM
J Urol; 2008 Jan; 179(1):81-6; discussion 86. PubMed ID: 17997441
[TBL] [Abstract][Full Text] [Related]
17. Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma.
Elfiky AA; Cho DC; McDermott DF; Rosenberg JE; Fortner B; Antràs L; Chen K; Sheng Duh M; Jayawant SS; Oh WK; Atkins MB; Choueiri TK
Urol Oncol; 2011; 29(6):756-63. PubMed ID: 20451414
[TBL] [Abstract][Full Text] [Related]
18. Long-term response with sunitinib for metastatic renal cell carcinoma.
Ronnen EA; Kondagunta GV; Ginsberg MS; Russo P; Motzer RJ
Urology; 2006 Sep; 68(3):672.e19-20. PubMed ID: 16979716
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib and sunitinib: novel targeted therapies for renal cell cancer.
Grandinetti CA; Goldspiel BR
Pharmacotherapy; 2007 Aug; 27(8):1125-44. PubMed ID: 17655513
[TBL] [Abstract][Full Text] [Related]
20. Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum.
Argani P; Olgac S; Tickoo SK; Goldfischer M; Moch H; Chan DY; Eble JN; Bonsib SM; Jimeno M; Lloreta J; Billis A; Hicks J; De Marzo AM; Reuter VE; Ladanyi M
Am J Surg Pathol; 2007 Aug; 31(8):1149-60. PubMed ID: 17667536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
